DDInter470 DDInter899
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dalteparin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinapril
Dalteparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Dalteparin {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Dalteparin {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Dalteparin may cause a minor interaction that can limit clinical effects when taken with Capsicum
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Dalteparin may lead to a major life threatening interaction when taken with Ticlopidine
Dalteparin may lead to a major life threatening interaction when taken with Ponatinib